INDV N logo

Indivior BMV:INDV N Stock Report

Last Price

Mex$314.49

Market Cap

Mex$42.6b

7D

-51.3%

1Y

-51.3%

Updated

11 Oct, 2022

Data

Company Financials +

INDV N Stock Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

INDV N fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Indivior PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Indivior
Historical stock prices
Current Share PriceUK£314.49
52 Week HighUK£0
52 Week LowUK£0
Beta-0.17
1 Month Change-51.30%
3 Month Change-51.30%
1 Year Change-51.30%
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.30%

Recent News & Updates

Recent updates

Shareholder Returns

INDV NMX PharmaceuticalsMX Market
7D-51.3%5.5%-0.7%
1Y-51.3%-7.4%4.1%

Return vs Industry: INDV N underperformed the MX Pharmaceuticals industry which returned -15% over the past year.

Return vs Market: INDV N underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is INDV N's price volatile compared to industry and market?
INDV N volatility
INDV N Average Weekly Movement0%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement3.8%
10% most volatile stocks in MX Market6.2%
10% least volatile stocks in MX Market2.1%

Stable Share Price: INDV N's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine INDV N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014900Mark Crossleyhttps://www.indivior.com

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex.

Indivior PLC Fundamentals Summary

How do Indivior's earnings and revenue compare to its market cap?
INDV N fundamental statistics
Market capMex$42.64b
Earnings (TTM)Mex$3.03b
Revenue (TTM)Mex$16.73b

14.1x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDV N income statement (TTM)
RevenueUS$838.00m
Cost of RevenueUS$140.00m
Gross ProfitUS$698.00m
Other ExpensesUS$546.00m
EarningsUS$152.00m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 27, 2022

Earnings per share (EPS)1.10
Gross Margin83.29%
Net Profit Margin18.14%
Debt/Equity Ratio104.3%

How did INDV N perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.